Article Text

Download PDFPDF

Atrophic vulvovaginitis in women aged 50 years and above, both current and non-users of hormone replacement therapy, attending a genitourinary medicine clinic
  1. Jean Tobin, FRCOG, MFFP, Consultant and
  2. Veerakathy Harindra, FRCP, Consultant
  1. Department of Genitourinary Medicine, St Mary's Hospital, Portsmouth PO3 6AD, UK
  1. Correspondence Dr J M Tobin, Consultant, Department of Genitourinary Medicine, St Mary's Hospital, Milton Road, Portsmouth PO3 6AD, UK. Tel: +44 (0) 23 9286 6790


Introduction In women aged 50 years and over attending a genitourinary medicine (GUM) department the commonest presentation was with symptoms of vulval soreness, irritation or dryness. Atrophic vulvovaginitis (AVV) was the commonest diagnosis made. This study was undertaken to determine if the presence of AVV was related to the use, or not, of systemic hormone replacement therapy (HRT).

Method A prospective study was made of all women aged 50 years and over attending a GUM department over a 3-month period.

Results Of the 124 women seen in this age group, 60 (40%) had AVV and 28 (23%) had vaginal candidiasis. No difference was found in current users or non-users of HRT.

Conclusion Accurate diagnosis is essential in women with vulval symptoms to ensure that appropriate therapy is given. In the present study symptomatic women aged 50 years and over were more likely to have AVV than candidiasis irrespective of their use of systemic HRT.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.